The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide-vincristine-doxorubicin-methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis

被引：33

作者：

Wu, Ping ^{[1
]}

Davies, Faith E. ^{[1
]}

Horton, Clive ^{[1
]}

Jenner, Matthew W. ^{[1
]}

Krishnan, Biju ^{[1
]}

Alvares, Caroline L. ^{[1
]}

Saso, Radovan ^{[1
]}

McCormack, Rita ^{[1
]}

Dines, Sharon ^{[1
]}

Treleaven, Jennifer G. ^{[1
]}

Potter, Michael N. ^{[1
]}

Ethell, Mark E. ^{[1
]}

Morgan, Gareth J. ^{[1
]}

机构：

[1] Royal Marsden Hosp, Haematooncol Unit, Sutton SM2 5PT, Surrey, England

来源：

LEUKEMIA & LYMPHOMA | 2006年 / 47卷 / 11期

关键词：

myeloma; thalidomide; autologous transplantation; CTD; CVAMP;

D O I：

10.1080/10428190600821955

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A retrospective case-matched study was conducted to compare the oral regimen CTD (cyclophosphamide-thalidomide-dexamethasone) and infusional CVAMP (cyclophosphamide-vincristine-doxorubicin-methylprednisolone) as induction therapy followed by autologous peripheral blood stem-cell transplantation (PBSCT) for newly diagnosed multiple myeloma patients. The response rate after three cycles of treatment was statistically higher with CTD (n = 27) compared to CVAMP (n = 27) (89% vs. 56%, P = 0.016). Toxicity studies showed more neutropenia (grade 3/4) (4% vs. 60%, P = 0.0002) with CVAMP and more thrombotic episodes with CTD (11% vs. 4%). CTD may emerge as the superior induction regimen prior to PBSCT, in terms of high efficacy and better tolerability.

引用

页码：2335 / 2338

页数：4

共 21 条

[1] RETRACTED: First-line thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (<61 years) with symptomatic multiple myeloma (Retracted Article. See vol 43, pg 893, 2009) [J].

Abdelkefi, A ;

Torjman, L ;

Ben Romdhane, N ;

Ladeb, S ;

El Omri, H ;

Ben Othman, T ;

Elloumi, M ;

Bellaj, H ;

Lakhal, A ;

Jeddi, R ;

Aissaouï, L ;

Saad, A ;

Hsaïri, M ;

Boukef, K ;

Dellagi, K ;

Ben Abdeladhim, A .

BONE MARROW TRANSPLANTATION, 2005, 36 (03) :193-198

[2] Myeloma - Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT [J].

Ahmad, I ;

Islam, T ;

Chanan-Khan, A ;

Hahn, T ;

Wentling, D ;

Becker, JL ;

McCarthy, PL ;

Alam, AR .

BONE MARROW TRANSPLANTATION, 2002, 29 (07) :577-580

[3] Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments [J].

Alvares, CL ;

Davies, FE ;

Horton, CS ;

Patel, G ;

Powles, R ;

Sirohi, B ;

Zuha, R ;

Gatt, A ;

Saso, R ;

Treleaven, JG ;

Dearden, CE ;

Potter, MN ;

Ethell, ME ;

Morgan, GJ .

BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (05) :607-614

[4] A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].

Attal, M ;

Harousseau, JL ;

Stoppa, AM ;

Sotto, JJ ;

Fuzibet, JG ;

Rossi, JF ;

Casassus, P ;

Maisonneuve, H ;

Facon, T ;

Ifrah, N ;

Payen, C ;

Bataille, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97

[5] The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma [J].

Baz, R ;

Li, L ;

Kottke-Marchant, K ;

Srkalovic, G ;

McGowan, B ;

Yiannaki, E ;

Karam, MA ;

Faiman, B ;

Jawde, RA ;

Andresen, S ;

Zeldis, J ;

Hussein, MA .

MAYO CLINIC PROCEEDINGS, 2005, 80 (12) :1568-1574

[6]

Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x

[7]

Cavo M, 2004, HAEMATOLOGICA, V89, P826

[8] Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma [J].

Cavo, M ;

Zamagni, E ;

Tosi, P ;

Tacchetti, P ;

Cellini, C ;

Cangini, D ;

de Vivo, A ;

Testoni, N ;

Nicci, C ;

Terragna, C ;

Grafone, T ;

Perrone, G ;

Ceccolini, M ;

Tura, S ;

Baccarani, M .

BLOOD, 2005, 106 (01) :35-39

[9]

Cavo M, 2002, HAEMATOLOGICA, V87, P934

[10] High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma [J].

Child, JA ;

Morgan, GJ ;

Davies, FE ;

Owen, RG ;

Bell, SE ;

Hawkins, K ;

Brown, J ;

Drayson, MT ;

Selby, PJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (19) :1875-1883

← 1 2 3 →